TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of transarterial
chemoembolization (TACE) combined with programmed cell death protein-1 (PD-1) antibody
compared with TACE Alone in patients with unresectable hepatocellular carcinoma (HCC)
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangzhou No.12 People's Hospital Kaiping Central Hospital